Posted by utopizen on September 13, 2002, at 15:39:23
In reply to Press release, info on Desoxyn marketing, posted by utopizen on September 13, 2002, at 15:07:45
CONSUMER CONTACT:
Abbot
1-800-441-4987Ovation Pharm.
847-955-9000PHYSICIAN CONTACT:
Ovation Pharm.
888-514-5204Please note: I am obviously unaffiliated with either company. I simply wanted to spread the word, since the media and ADD sites seem to have overlooked this rather signifigant event. This could mean the re-making of how America perceives methamphetamine as treatment for ADD, something Abbott neglected to do.
-----------------------------------
Ovation Pharmaceuticals, Inc. Acquires Tranxene And Desoxyn From Abbott Laboratories (ABT)
LINCOLNSHIRE, Ill., Aug. 22 /PRNewswire/ -- Ovation Pharmaceuticals, a specialty pharmaceutical company, today announced the acquisition of Tranxene(R) (clorazepate dipotassium) and Desoxyn(R) (methamphetamine hydrochloride) from Abbott Laboratories. As part of the acquisition, Abbott will continue to manufacture both products for a period of time under a product supply agreement with Ovation. The two FDA-approved products, both designed for the treatment of central nervous system ("CNS") disorders, mark Ovation's first CNS products since partnering with GTCR Golder Rauner, LLC. In April of this year, Ovation received a commitment for $150 million in equity financing from GTCR for the purpose of enabling Ovation to acquire under-promoted branded pharmaceutical products."These acquisitions constitute an important milestone for Ovation, as they are the first products in our CNS portfolio," said Jeffrey S. Aronin, Ovation's President and Founder. "Both products fit well into our strategy of acquiring under-promoted pharmaceutical products in specialty-physician markets. These products target CNS conditions with high levels of unmet medical need and large refractory and treatment-resistant populations," Aronin said. "For these reasons, Tranxene and Desoxyn give us a strong platform for building our CNS franchise."
Tranxene is a benzodiazepine used for the management of anxiety disorders, as adjunctive therapy in the management of partial seizures due to epilepsy, and for symptomatic relief of acute alcohol withdrawal. It is available as a multi-dose-per-day tablet (Tranxene T-Tab(R)) and a single-dose-per-day tablet (Tranxene SD(TM)). Desoxyn is an amphetamine that is approved for the treatment of Attention Deficit with Hyperactivity Disorder (ADHD) and exogenous (caused by external factors) obesity. Desoxyn is available as a multi-dose-per-day tablet.
The two medications become part of a product portfolio that Ovation is building in neurology, oncology and other specialty therapeutic areas. Ovation's commercial activities with these two drugs will center on increasing sales through focused sales and marketing activities targeting the concentrated population of neurology and psychiatry prescribers as well as through product improvement and development efforts.
Tranxene, a schedule IV controlled substance, should not be taken by patients with known hypersensitivity to the drug, those with acute narrowangle glaucoma, patients less than nine years of age, or those who are pregnant and is not recommended for use in depressive neuroses or psychotic reactions. Patients taking Tranxene should not engage in hazardous occupations requiring mental alertness and should not use Tranxene with other CNS-depressant drugs. After extended therapy, abrupt discontinuation of Tranxene should be avoided, and caution should be observed in patients who have potential for drug dependence.
Desoxyn, a schedule II controlled substance, has a high potential for abuse. When prescribed for exogenous obesity, Desoxyn should be tried only in weight reduction programs for patients in whom alternative therapy has been ineffective. Desoxyn should not be taken during or within 14 days following the administration of monoamine oxidase inhibitors, and should not be taken by patients with glaucoma, advanced arteriosclerosis, symptomatic cardiovascular disease, hypertension, hyperthyroidism or known hypersensitivity to sympathomimetic amines. Desoxyn should not be given to patients who are in an agitated state or who have a history of drug abuse.
About Ovation Pharmaceuticals, Inc.
Ovation Pharmaceuticals, Inc. is a specialty pharmaceutical company that acquires under-promoted branded pharmaceutical products and promising late- stage development products. Ovation increases the sales of acquired products through active selling efforts, creative marketing programs, and product life cycle activities that focus on developing new formulations, new indications, and other product improvements. Ovation is privately held and based in the Chicago area. For more information, visit www.ovationpharma.com .
Tranxene, Desoxyn, Tranxene T-Tab and Tranxene SD are exclusive trademarks of Ovation Pharmaceuticals, Inc.
poster:utopizen
thread:119750
URL: http://www.dr-bob.org/babble/20020906/msgs/119757.html